(2)b Division of Endocrinology, Department of Medicine , Beth Israel Deaconess 
Medical Center, Harvard Medical School , Boston , MA , USA.
(3)c Keck School of Medicine of the University of Southern California , Los 
Angeles , CA , USA.
(4)d Lilly Corporate Center , Eli Lilly & Company , Indianapolis , IN , USA.

Type 2 diabetes mellitus (T2DM) is a growing problem in the USA, affecting 30.3 
million Americans, or 9.4% of the US population. Given that T2DM is a 
progressive disease, intensification of rapid acting insulin (RAI) to address 
hyperglycaemia is often required. The American Diabetes Association and the 
European Association for the Study of Diabetes recommend individualizing the 
treatment approach to glucose control, considering factors such as age, health 
behaviours, comorbidities and life expectancy. There are several validated 
treatment algorithms in the literature, which can be helpful for providing 
guidance on initiation of RAI while simultaneously considering patient 
preferences and clinical needs during treatment intensification. This paper 
provides expert recommendations on prandial insulin regimens and how to use 
treatment algorithms to promote better glucose control through best practice 
guidelines. To help patients reach HbA1c targets through treatment 
intensification, the FullSTEP, SimpleSTEP, ExtraSTEP and AUTONOMY algorithms are 
discussed in this paper. KEY MESSAGES Clinical inertia should be prevented with 
timely intensification of therapy when HbA1c levels are greater than 7% (or 
rising above a patient's individual target) according to national guidelines. 
Increased personalization in the intensification of T2D treatment is necessary 
to improve HbA1c targets while addressing risk of hypoglycaemia, concern about 
weight gain, and overall health goals. Healthcare providers are encouraged to 
address glycaemic control with a variety of strategies, including prandial 
insulin, while developing evidence-based treatment plans on the basis of 
algorithms discussed in the literature.

DOI: 10.1080/07853890.2018.1493216
PMID: 30103624 [Indexed for MEDLINE]


774. Int J Equity Health. 2018 Aug 13;17(1):117. doi: 10.1186/s12939-018-0832-y.

Punching above their weight: a network to understand broader determinants of 
increasing life expectancy.

Baum F(1), Popay J(2), Delany-Crowe T(3), Freeman T(3), Musolino C(3), 
Alvarez-Dardet C(4), Ariyaratne V(5), Baral K(6), Basinga P(7), Bassett M(8), 
Bishai DM(9), Chopra M(10), Friel S(11)(12), Giugliani E(13), Hashimoto H(14), 
Macinko J(15), McKee M(16), Nguyen HT(17), Schaay N(18), Solar O(19), 
Thiagarajan S(20), Sanders D(21).

Author information:
(1)Southgate Institute for Health, Society & Equity, Flinders University, 
Adelaide, South Australia, Australia. fran.baum@flinders.edu.au.
(2)Institute for Health Research, Lancaster University, Bailrigg, Lancaster, UK.
(3)Southgate Institute for Health, Society & Equity, Flinders University, 
Adelaide, South Australia, Australia.
(4)The Observatory of Public Policies and Health, Center for Research in 
Epidemiology and Public Health, University of Alicante, Alicante, Spain.
(5)Sarvodaya Shramadana Movement, Sarvodaya Headquarters "Damsak Mandira", 
Moratuwa, Sri Lanka.
(6)Department of Community Health Sciences, Patan Academy of Health Sciences, 
Kathmandu, Nepal.
(7)Integrated Delivery Country Primary Health Care, Bill and Melinda Gates 
Foundation, Abuja, Nigeria.
(8)New York City Department of Health and Mental Hygiene, Office of General 
Counsel, Long Island City, New York, USA.
(9)Population, Family, and Reproductive Health, Johns Hopkins University 
Bloomberg School of Public Health, Baltimore, Maryland, USA.
(10)World Bank, Washington, USA.
(11)School of Regulation and Global Governance (RegNet), Australian National 
University, Canberra, Australian Capital Territory, Australia.
(12)College of Asia and the Pacific, Australian National University, Canberra, 
Australian Capital Territory, Australia.
(13)School of Medicine, Department of Pediatrics and Child Care, Federal 
University of Rio Grande do Sul, Porto Alegre, Brazil.
(14)Health Economics and Epidemiology Research, School of Public Health, 
University of Tokyo, Tokyo, Japan.
(15)Departments of Health Policy and Management and Community Health Sciences, 
UCLA Fielding School of Public Health, Los Angeles, California, USA.
(16)European Public Health, London School of Hygiene and Tropical Medicine, 
London, UK.
(17)Department of Health Management and Organization, Hanoi Medical University, 
Hanoi, Vietnam.
(18)Faculty of Community and Health, School of Public Health, University of the 
Western Cape, Bellville, Republic of South Africa.
(19)Faculty of Medicine, Programa de Salud Ocupacional, Académico, Escuela de 
Salud Pública, Universidad de Chile, Santiago, Chile.
(20)School of Health Systems Research, Tata Institute of Social Sciences, 
Mumbai, India.
(21)School of Public Health, University of the Western Cape, Bellville, South 
Africa.

BACKGROUND: Life expectancy initially improves rapidly with economic development 
but then tails off. Yet, at any level of economic development, some countries do 
better, and some worse, than expected - they either punch above or below their 
weight. Why this is the case has been previously researched but no full 
explanation of the complexity of this phenomenon is available.
NEW RESEARCH NETWORK: In order to advance understanding, the newly formed 
Punching Above Their Weight Research Network has developed a model to frame 
future research. It provides for consideration of the following influences 
within a country: political and institutional context and history; economic and 
social policies; scope for democratic participation; extent of health promoting 
policies affecting socio-economic inequities; gender roles and power dynamics; 
the extent of civil society activity and disease burdens.
CONCLUSION: Further research using this framework has considerable potential to 
advance effective policies to advance health and equity.

DOI: 10.1186/s12939-018-0832-y
PMCID: PMC6090609
PMID: 30103760 [Indexed for MEDLINE]

Conflict of interest statement: Not applicable. Not applicable. The authors 
declare that they have no competing interests. Springer Nature remains neutral 
with regard to jurisdictional claims in published maps and institutional 
affiliations.


775. Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 
10.1016/S2214-109X(18)30306-1.

Prescribing patterns of evidence-based heart failure pharmacotherapy and 
outcomes in the ASIAN-HF registry: a cohort study.

Teng TK(1), Tromp J(2), Tay WT(3), Anand I(4), Ouwerkerk W(5), Chopra V(6), 
Wander GS(7), Yap JJ(3), MacDonald MR(8), Xu CF(3), Chia YM(9), Shimizu W(10); 
ASIAN-HF investigators; Richards AM(11), Voors A(12), Lam CS(13).

Author information:
(1)National Heart Centre Singapore, Singapore, Singapore; School of Population 
and Global Health, University of Western Australia, WA, Australia.
(2)National Heart Centre Singapore, Singapore, Singapore; Department of 
Cardiology, University Medical Center Groningen, Groningen, Netherlands.
(3)National Heart Centre Singapore, Singapore, Singapore.
(4)Veterans Affairs Medical Center, Minneapolis, MN, USA.
(5)Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, 
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
(6)Medanta, Gurgaon, India.
(7)Dayanand Medical College and Hospital, Ludhiana, India.
(8)Changi General Hospital, Singapore, Singapore.
(9)Duke-National University of Singapore Medical School, Singapore, Singapore.
(10)Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
(11)Cardiovascular Research Institute, National University Heart Centre, 
Singapore, Singapore; University of Otago, Dunedin, New Zealand.
(12)Department of Cardiology, University Medical Center Groningen, Groningen, 
Netherlands.
(13)National Heart Centre Singapore, Singapore, Singapore; Department of 
Cardiology, University Medical Center Groningen, Groningen, Netherlands; 
Duke-National University of Singapore Medical School, Singapore, Singapore. 
Electronic address: carolyn.lam@duke-nus.edu.sg.

Comment in
    Lancet Glob Health. 2018 Sep;6(9):e942-e943.

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II 
receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists 
(MRAs) are of proven benefit and are recommended by guidelines for management of 
patients with heart failure and reduced ejection fraction (HFrEF). We aimed to 
examine the first prospective multinational data from Asia on prescribing 
patterns of guideline-directed medical therapies and analyse its effect on 
outcomes.
METHODS: In the prospective multinational ASIAN-HF registry (with enrolment from 
46 centres in 11 countries in Asia), we enrolled patients aged 18 years or 
older, with symptomatic heart failure (stage C, with at least one episode of 
decompensated heart failure in the past 6 months that resulted in admission to 
hospital or was treated in an outpatient clinic) and left ventricular systolic 
dysfunction (ejection fraction ≤40% on baseline echocardiography, consistent 
with 2016 European Society of Cardiology guidelines). We excluded patients with 
heart failure caused by severe valvular heart disease, life-threatening 
comorbidity with a life expectancy of less than 1 year, who were unable or 
unwilling to give consent, or who had concurrent participation in a clinical 
trial. Patients were followed up for 3 years for the outcomes of death and 
cause-specific admittance to hospital. Primary outcomes were uptake of 
guideline-directed medical therapies (as proportions) by therapeutic class, 
achieved doses as proportions of guideline-recommended doses, and their 
association with 1-year composite outcome of all-cause death or admittance to 
hospital because of heart failure. This study is registered with 
ClinicalTrials.gov, number NCT01633398.
FINDINGS: Between Oct 1, 2012, and Dec 31, 2015, we enrolled 5276 patients with 
HFrEF (mean age 59·6 years [SD 13·2], 77% men, body-mass index 24·9 kg/m2 [5·1], 
33% New York Heart Association class III or IV). Follow-up data were available 
for 4544 (90%) of 5061 eligible patients taking medication for heart failure, 
with median follow-up of 417 days (IQR 214-735). ACE inhibitors or ARBs were 
prescribed to 3868 (77%) of 5005 patients, β blockers to 3975 (79%) of 5061, and 
MRAs to 2998 (58%) of 5205, with substantial regional variation. 
Guideline-recommended dose was achieved in only 17% of cases for ACE inhibitors 
or ARB, 13% for β blockers, and 29% for MRAs. Country (all three drug classes), 
increasing body-mass index (ACE inhibitors or ARBs and MRAs), and in-patient 
recruitment (ACE inhibitors or ARBs and β blockers) were associated with 
attainment of guideline-recommended dose (all p<0·05). When adjusted for 
indication bias, increasing drug doses, from low dose (1-<25% of 
guideline-recommended dose) upwards were associated with lower hazards of a 
1-year composite outcome for ACE inhibitors or ARBs and β blockers compared with 
non-users. The lowest adjusted hazards were in the group that attained 
guideline-recommended doses above 50% (hazard ratio [HR] 0·54, 95% CI 0·50-0·58 
for ACE inhibitors or ARBs [50-99·9%]; HR 0·47, 0·46-0·50 for β blockers, and HR 
0·77, 0·72-0·81 for MRAs [≥100%]).
INTERPRETATION: Guideline-directed medical therapies at recommended doses are 
underutilised in patients with HFrEF. Improved uptake and uptitration of 
guideline-directed medical therapies are needed for better patient outcomes.
FUNDING: National Medical Research Council (Singapore), A*STAR Biomedical 
Research Council ATTRaCT program, Boston Scientific Investigator Sponsored 
Research program, and Bayer.

Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open 
access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. 
All rights reserved.

DOI: 10.1016/S2214-109X(18)30306-1
PMID: 30103979 [Indexed for MEDLINE]


776. Cancer Treat Res Commun. 2018;14:21-25. doi: 10.1016/j.ctarc.2017.11.003.
Epub  2017 Nov 10.

Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive 
chemotherapy regimen? A cost-utility analysis.

Billingsley CC(1), Cohn DE(2), Crim AK(3), Li Q(4), O'Malley DM(2), Havrilesky 
LJ(5).

Author information:
(1)The Ohio State University, Division of Gynecologic Oncology, Department of 
Obstetrics and Gynecology, M210 Starling Loving, 320 West 10th Avenue, Columbus, 
OH 43210, United States. Electronic address: caroline.billingsley@osumc.edu.
(2)The Ohio State University, Division of Gynecologic Oncology, Department of 
Obstetrics and Gynecology, M210 Starling Loving, 320 West 10th Avenue, Columbus, 
OH 43210, United States.
(3)The Ohio State University, Department of Obstetrics and Gynecology, M210 
Starling Loving, 320 West 10th Avenue, Columbus, OH 43210, United States.
(4)The Ohio State University, Department of Pharmacy, Arthur G. James Cancer 
Hospital and Richard J. Solove Research Institute, M210 Starling Loving, 320 
West 10th Avenue, Columbus, OH 43210, United States.
(5)Duke University, Division of Gynecologic Oncology, Department of Obstetrics 
and Gynecology, Duke Cancer Institute, United States.

BACKGROUND: There is recent evidence supporting the safety and efficacy of 
same-day dosing of pegfilgrastim in patients undergoing chemotherapy.
OBJECTIVE: To determine the cost-effectiveness of pegfilgrastim on day 1 (D1) 
versus day 2 (D2) for primary prevention of neutropenia in women receiving 
chemotherapy.
MATERIALS AND METHODS: A cost-utility model was designed comparing standard D2 
versus D1 administration of pegfilgrastim to ovarian cancer patients receiving 
chemotherapy with an intermediate risk (10-15%) of febrile neutropenia (FN). 
Rates of FN despite prophylaxis were modeled as 10% for D1 and 5% for D2. 
Societal costs associated with D2 injection ($175.71) were incorporated. Quality 
of life (QOL) was modeled from published data; we assumed a small decrement in 
QOL on treatment days. Sensitivity analyses were performed.
RESULTS: D1 administration was less costly ($17,195 versus $17,681) and resulted 
in higher QOL (0.2298 quality adjusted life years (QALYs) versus 0.2288 QALYs) 
than D2. Results were sensitive to the risk of FN. D1 remained dominant or 
cost-effective (ICER less than $50,000/QALY) compared to D2 if the FN rate with 
D1 was assumed less than 14.5% (baseline estimate 10%). If the FN rate with D1 
was assumed greater than or equal to 15%, D1 was not cost-effective compared to 
D2, with an ICER greater than $100,000/QALY. Findings are insensitive to 
variations in the modeled cost of treating FN, the additional cost of D2 
injection, and the reduced QOL associated with treatment visits.
CONCLUSION: Administration of D1 pegfilgrastim is cost-effective in women with 
ovarian cancer who are treated with intermediate risk chemotherapy.

Copyright © 2017. Published by Elsevier Ltd.

DOI: 10.1016/j.ctarc.2017.11.003
PMID: 30104004 [Indexed for MEDLINE]


777. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017.
 Epub 2018 Aug 10.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic 
non-squamous non-small cell lung cancer (NSCLC).

Panje CM(1), Dedes KJ(2), Matter-Walstra K(3), Schwenkglenks M(4), Gautschi 
O(5), Siano M(6), Aebersold DM(7), Plasswilm L(8), Lupatsch JE(3); Swiss Group 
for Clinical Cancer Research (SAKK).

Author information:
(1)Department of Radiation Oncology, Cantonal Hospital St. Gallen, Switzerland. 
Electronic address: cedric.panje@kssg.ch.
(2)Department of Gynecology, University Hospital Zurich, Switzerland.
(3)Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, 
Switzerland; Institute of Pharmaceutical Medicine, University of Basel, 
Switzerland.
(4)Institute of Pharmaceutical Medicine, University of Basel, Switzerland.
(5)Medical Oncology, Department of Internal Medicine, Cantonal Hospital Lucerne, 
Switzerland.
(6)Department of Medical Oncology, Cantonal Hospital St. Gallen, Switzerland.
(7)Department of Radiation Oncology, University of Bern, Switzerland.
(8)Department of Radiation Oncology, Cantonal Hospital St. Gallen, Switzerland; 
Department of Radiation Oncology, University of Bern, Switzerland.

BACKGROUND: Novel systemic therapies have improved the prognosis of metastatic 
non-small cell lung cancer (NSCLC), but costs of some of these drugs are a 
matter of ongoing debate. More recently, local therapies (LT) such as 
radiotherapy and surgery have been suggested as additional treatment in 
oligometastatic NSCLC demonstrating an improved progression-free survival (PFS) 
in a phase II trial compared to maintenance chemotherapy (MC) alone. The aim of 
this analysis was to assess the cost-effectiveness of local therapies in 
oligometastatic NSCLC.
METHODS: We constructed a Markov model comparing the cost-effectiveness of LT 
versus MC for oligometastatic NSCLC from the Swiss healthcare payer's 
perspective. Treatment specifications and PFS were based on the phase II trial 
(NCT01725165). Overall survival (OS) was inferred from a recent phase III trial. 
Utilities were taken from published data. Primary outcome was the incremental 
cost-effectiveness-ratio (ICER, costs in Swiss Francs (CHF) per quality-adjusted 
life-year (QALY) gained).
RESULTS: PFS in the model was 3.8 months for MC and 11.4 months for LT (compared 
to 3.9 months and 11.9 months in the trial). OS in the model was 15.5 months in 
both arms. LT was cost-effective with a gain of 0.24 QALYs at an additional cost 
of CHF 9641, resulting in an ICER of CHF 40,972/QALY gained. Probabilistic 
sensitivity analyses demonstrated that LT was dominant or cost-effective at a 
willingness-to-pay threshold of CHF 100,000 per QALY in 61.7% of the 
simulations.
CONCLUSIONS: LT may be cost-effective for selected patients with oligometastatic 
NSCLC responding to first-line systemic therapy.

Copyright © 2018 Elsevier B.V. All rights reserved.

DOI: 10.1016/j.radonc.2018.07.017
PMID: 30104008 [Indexed for MEDLINE]


778. J Thorac Cardiovasc Surg. 2018 Dec;156(6):2285-2294.e2. doi: 
10.1016/j.jtcvs.2018.06.040. Epub 2018 Jul 18.

Long-term results of the modified Konno procedure in high-risk children with 
obstructive hypertrophic cardiomyopathy.

Laredo M(1), Khraiche D(2), Raisky O(2), Gaudin R(2), Bajolle F(2), Maltret 
A(2), Chevret S(3), Bonnet D(2), Vouhé PR(2).

Author information:
(1)Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre 
de référence des Malformations Cardiaques Congénitales Complexes-M3C, Hôpital 
Necker Enfants Malades, APHP, Université Paris Descartes, Sorbonne Paris-Cité, 
Paris, France. Electronic address: mik.laredo@gmail.com.
(2)Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre 
de référence des Malformations Cardiaques Congénitales Complexes-M3C, Hôpital 
Necker Enfants Malades, APHP, Université Paris Descartes, Sorbonne Paris-Cité, 
Paris, France.
(3)Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, 
Université Paris Diderot, Sorbonne Paris-Cité, Paris, France.

Comment in
    J Thorac Cardiovasc Surg. 2018 Dec;156(6):2295-2296.
    J Thorac Cardiovasc Surg. 2018 Dec;156(6):2283-2284.

OBJECTIVE: Transaortic septal myectomy is the gold standard surgery in 
obstructive hypertrophic cardiomyopathy, but it is not optimal for children aged 
less than 5 years and with right ventricular outflow tract obstruction. We 
evaluated outcomes with the modified Konno procedure in children with severe 
forms of obstructive hypertrophic cardiomyopathy.
METHODS: A total of 79 consecutive children who underwent the modified Konno 
procedure in our center between 1991 and 2016 were included.
RESULTS: Clinical features included age less than 5 years (38%), maximal septal 
thickness 25 mm or more (32%), extension to the left ventricular apex (29%), and 
right ventricular outflow tract obstruction (28%). In total, 25% of patients had 
Noonan syndrome. Five children (6%) aged less than 15 months with Noonan 
syndrome and biventricular obstruction died in the hospital. Mean follow-up was 
6 ± 5.7 years. Survival without death and heart transplantation was 82% at 
20 years. Atrioventricular block occurred in 9 patients (11%) and was associated 
with right ventricular outflow tract obstruction and surgery before 2010. Death, 
resuscitated sudden cardiac death, and appropriate implantable defibrillator 
shock were associated with maximal septal thickness before surgery (adjusted 
odds ratio, 1.20; 95% confidence interval, 1.07-1.35; P = .002) and need for an 
associated procedure (adjusted odds ratio, 8.84; 95% confidence interval, 
2.01-38.93; P = .004). There was no case of recurrent obstruction. Reoperation 
was required in 4 patients (5%) for other reasons.
CONCLUSIONS: The modified Konno procedure provided durable obstruction relief 
and good long-term survival in children with severe forms of obstructive 
hypertrophic cardiomyopathy. Children with Noonan syndrome undergoing surgery 
early in life were at higher risk of early mortality.

Copyright © 2018 The American Association for Thoracic Surgery. Published by 
Elsevier Inc. All rights reserved.

DOI: 10.1016/j.jtcvs.2018.06.040
PMID: 30104063 [Indexed for MEDLINE]


779. BMJ. 2018 Aug 13;362:k3491. doi: 10.1136/bmj.k3491.

Sixty seconds on . . . life expectancy.

Hawkes N(1).

Author information:
(1)London.

DOI: 10.1136/bmj.k3491
PMID: 30104287


780. BMJ Open. 2018 Aug 13;8(8):e017511. doi: 10.1136/bmjopen-2017-017511.

Cost-effectiveness of habit-based advice for weight control versus usual care in 
general practice in the Ten Top Tips (10TT) trial: economic evaluation based on 
a randomised controlled trial.

Patel N(1), Beeken RJ(2)(3), Leurent B(4), Omar RZ(5), Nazareth I(6), Morris 
S(1).

Author information:
(1)Department of Applied Health Research, University College London, London, UK.
(2)Department of Behavioural Science and Health, University College London, 
London, UK.
(3)Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
(4)Department of Medical Statistics, London School of Hygiene & Tropical 
Medicine, London, UK.
(5)Department of Statistical Science, University College London, London, UK.
(6)Department of Primary Care and Population Health, University College London, 
London, UK.

OBJECTIVE: Ten Top Tips (10TT) is a primary care-led behavioural intervention 
which aims to help adults reduce and manage their weight by following 10 weight 
loss tips. The intervention promotes habit formation to encourage long-term 
behavioural changes. The aim of this study was to estimate the 
cost-effectiveness of 10TT in general practice from the perspective of the UK 
National Health Service.
DESIGN: An economic evaluation was conducted alongside an individually 
randomised controlled trial.
SETTING: 14 general practitioner practices in England.
PARTICIPANTS: All patients were aged ≥18 years, with body mass index ≥30 kg/m2. 
A total of 537 patients were recruited; 270 received the usual care offered by 
their practices and 267 received the 10TT intervention.
OUTCOMES MEASURES: Health service use and quality-adjusted life years (QALYs) 
were measured over 2 years. Analysis was conducted in terms of incremental net 
monetary benefits (NMBs), using non-parametric bootstrapping and multiple 
imputation.
RESULTS: Over a 2-year time horizon, the mean costs and QALYs per patient in the 
10TT group were £1889 (95% CI £1522 to £2566) and 1.51 (95% CI 1.44 to 1.58). 
The mean costs and QALYs for usual care were £1925 (95% CI £1599 to £2251) and 
1.51 (95% CI 1.45 to 1.57), respectively. This generated a mean cost difference 
of -£36 (95% CI -£512 to £441) and a mean QALY difference of 0.001 (95% CI 
-0.080 to 0.082). The incremental NMB for 10TT versus usual care was £49 (95% CI 
-£1709 to £1800) at a maximum willingness to pay for a QALY of £20 000. 10TT had 
a 52% probability of being cost-effective at this threshold.
CONCLUSIONS: Costs and QALYs for 10TT were not significantly different from 
usual care and therefore 10TT is as cost-effective as usual care. There was no 
evidence to recommend nor advice against offering 10TT to obese patients in 
general practices based on cost-effectiveness considerations.
TRIAL REGISTRATION NUMBER: ISRCTN16347068; Post-results.

© Article author(s) (or their employer(s) unless otherwise stated in the text of 
the article) 2018. All rights reserved. No commercial use is permitted unless 
otherwise expressly granted.

DOI: 10.1136/bmjopen-2017-017511
PMCID: PMC6091904
PMID: 30104307 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: None declared.781. Eur J Clin Nutr. 2019 Mar;73(3):395-400. doi: 10.1038/s41430-018-0270-3.
Epub  2018 Aug 13.

Dietary diversity and healthy life expectancy-an international comparative 
study.

Miyamoto K(1), Kawase F(2), Imai T(3), Sezaki A(3), Shimokata H(2).

Author information:
(1)Graduate School of Nutritional Science, Nagoya University of Arts and 
Sciences, Aichi, Japan. hike5843@yahoo.co.jp.
(2)Graduate School of Nutritional Science, Nagoya University of Arts and 
Sciences, Aichi, Japan.
(3)Department of Food Science and Nutrition, Doshisha Women's College of Liberal 
Arts, Kyoto, Japan.

BACKGROUND/OBJECTIVES: The prolongation of healthy life expectancy (HALE) is a 
core issue of health policy in many countries. The purpose of this study is to 
clarify the relationship between dietary diversity and HALE using international 
databases.
MATERIALS/METHODS: HALE data by country were derived from the Global Burden of 
Disease (GBD) 2015 database. Average food supply (g/day/capita) and energy 
supply (kcal/day/capita) by country, excluding loss between production and 
household, were obtained from the Food and Agriculture Organization of the 
United Nations Statistics Division database. Each food was sorted across 12 food 
groups, and dietary diversity was obtained from food groups using the 
Quantitative Index for Dietary Diversity (QUANTIDD). The cross-sectional and 
longitudinal associations between QUANTIDD and HALE were examined in the 
countries with populations of one million or greater.
RESULTS: Cross-sectional analysis showed that HALE was significantly associated 
with QUANTIDD (β = 99.9 ± 11.4, p < 0.001) in the single regression model and in 
the multiple regression model controlled for covariates (β = 36.4 ± 11.3, 
p = 0.002). Longitudinal analysis showed that HALE increased with QUANTIDD 
during the 15-year study period (β = 46.4 ± 5.1, p < 0.001), and this 
association was also significant when controlled for covariates (β = 39.7 ± 5.1, 
p < 0.001). Longitudinal association of QUANTIDD with the percentage difference 
between life expectancy and HALE controlled for covariates was significantly 
negative (β = - 1.3 ± 0.5, p = 0.011).
CONCLUSIONS: After controlling for socioeconomic indicators, longer healthy life 
is enjoyed by populations of countries with greater dietary diversity.

DOI: 10.1038/s41430-018-0270-3
PMID: 30104730 [Indexed for MEDLINE]


782. Bull World Health Organ. 2018 Aug 1;96(8):568-577. doi:
10.2471/BLT.18.207944.  Epub 2018 Jun 28.

Cost-effectiveness of risk-based breast cancer screening programme, China.

Sun L(1), Legood R(1), Sadique Z(1), Dos-Santos-Silva I(2), Yang L(3).

Author information:
(1)Department of Health Services Research and Policy, London School of Hygiene 
and Tropical Medicine, London, England.
(2)Department of Noncommunicable Disease Epidemiology, London School of Hygiene 
and Tropical Medicine, London, England.
(3)School of Public Health, Peking University, NO.38 Xueyuan Road, Haidian 
District, Beijing 100191, China.

OBJECTIVE: To model the cost-effectiveness of a risk-based breast cancer 
screening programme in urban China, launched in 2012, compared with no 
screening.
METHODS: We developed a Markov model to estimate the lifetime costs and effects, 
in terms of quality-adjusted life years (QALYs), of a breast cancer screening 
programme for high-risk women aged 40-69 years. We derived or adopted 
age-specific incidence and transition probability data, assuming a natural 
history progression between the stages of cancer, from other studies. We 
obtained lifetime direct and indirect treatment costs in 2014 United States 
dollars (US$) from surveys of breast cancer patients in 37 Chinese hospitals. To 
calculate QALYs, we derived utility scores from cross-sectional patient surveys. 
We evaluated incremental cost-effectiveness ratios for various scenarios for 
comparison with a willingness-to-pay threshold.
FINDINGS: Our baseline model of annual screening yielded an incremental 
cost-effectiveness ratio of US$ 8253/QALY, lower than the willingness-to-pay 
threshold of US$ 23 050/QALY. One-way and probabilistic sensitivity analyses 
demonstrated that the results are robust. In the exploration of various 
scenarios, screening every 3 years is the most cost-effective with an 
incremental cost-effectiveness ratio of US$ 6671/QALY. The cost-effectiveness of 
the screening is reduced if not all diagnosed women seek treatment. Finally, the 
economic benefit of screening women aged 45-69 years with both ultrasound and 
mammography, compared with mammography alone, is uncertain.
CONCLUSION: High-risk population-based breast cancer screening is cost-effective 
compared with no screening.

Publisher: OBJECTIF: Modéliser le rapport coût-efficacité d'un programme de 
dépistage du cancer du sein fondé sur les risques en Chine urbaine, lancé 
en 2012, comparé à l'absence de dépistage.
MÉTHODES: Nous avons élaboré un modèle de Markov pour estimer le coût et les 
effets portant sur la vie entière, au regard des années de vie pondérées par la 
qualité (QALY), d'un programme de dépistage du cancer du sein chez les femmes à 
haut risque âgées de 40 à 69 ans. Nous avons tiré ou adopté des données sur 
l'incidence selon l'âge et la probabilité de transition, dans l'hypothèse d'une 
évolution naturelle entre les phases du cancer, à partir d'autres études. Nous 
avons obtenu les coûts directs et indirects de traitement au cours d'une vie en 
dollars des États-Unis de 2014 ($US) à partir d'enquêtes menées auprès de 
patientes atteintes du cancer du sein dans 37 hôpitaux chinois. Pour calculer 
les QALY, nous avons déduit des scores d'utilité à partir d'enquêtes 
transversales auprès de patientes. Nous avons évalué le rapport coût-efficacité 
différentiel selon différents scénarios pour établir une comparaison avec un 
seuil de consentement à payer.
RÉSULTATS: Notre modèle de référence de dépistage annuel a donné un rapport 
coût-efficacité différentiel de 8253 $US/QALY, soit moins que le seuil de 
consentement à payer de 23 050 $US/QALY. Les analyses à un seul critère de 
classification et de sensibilité probabiliste ont démontré que les résultats 
sont fiables. L'examen de différents scénarios a révélé que le dépistage tous 
les 3 ans présente le meilleur rapport coût-efficacité, avec un rapport 
coût-efficacité différentiel de 6671 $US/QALY. Le rapport coût-efficacité du 
dépistage est réduit si toutes les femmes diagnostiquées ne se font pas soigner. 
Enfin, l'avantage économique lié au dépistage des femmes âgées de 45 à 69 ans 
par échographie et mammographie, comparé à un dépistage par mammographie 
uniquement, est incertain.
CONCLUSION: Le dépistage du cancer du sein dans les populations à haut risque 
présente un bon rapport coût-efficacité par rapport à l'absence de dépistage.

Publisher: OBJETIVO: Demostrar la rentabilidad de un programa de detección del 
cáncer de mama basado en el riesgo en las zonas urbanas de China, iniciado en 
2012, en comparación con la ausencia de detección.
MÉTODOS: Se desarrolló un modelo Markov para estimar los costes y efectos 
durante el ciclo vital, en términos de años de vida ajustados por calidad de 
vida (AVAC), de un programa de detección del cáncer de mama para mujeres con 
alto riesgo de entre 40 y 69 años de edad. Se obtuvieron o adoptaron datos de la 
probabilidad de incidencia y transición específicos por edad, sobre la hipótesis 
de una progresión de la historia natural entre los estadios del cáncer, a partir 
de otros estudios. Se obtuvieron los costes directos e indirectos del 
tratamiento vitalicio en dólares estadounidenses (USD) en 2014 a partir de 
encuestas a pacientes con cáncer de mama en 37 hospitales de China. Para 
calcular los AVAC, se derivaron las puntuaciones de los servicios públicos de 
las encuestas transversales a los pacientes. Se evaluaron las relaciones de 
rentabilidad incrementales para diversos escenarios en comparación con un umbral 
de la disposición a pagar.​: Resultados Nuestro modelo de referencia de 
detección anual reveló una relación de rentabilidad incremental de 8253 
USD/AVAC, por debajo del umbral de disposición a pagar de 23 050 USD/AVAC. Los 
análisis de sensibilidad unidireccionales y de probabilidad demostraron que los 
resultados son sólidos. En la exploración de varios escenarios, la detección 
cada 3 años es la más rentable, con una relación de rentabilidad incremental de 
6671 USD/AVAC. La rentabilidad de la detección se reduce si no todas las mujeres 
diagnosticadas buscan tratamiento. Finalmente, el beneficio económico de la 
detección en mujeres de 45 a 69 años de edad con ultrasonido y mamografía, en 
comparación con solo la mamografía, es incierto.
CONCLUSIÓN: La detección del cáncer de mama basada en la población de alto 
riesgo es rentable en comparación con la ausencia de detección.

Publisher: الغرض: وضع نموذج لفعالية التكلفة لبرنامج فحص سرطان الثدي القائم على 
المخاطر في الصين الحضرية، والذي تم إطلاقه في عام 2012، مقارنة بعدم إجراء فحص.
الطريقة: لقد قمنا بتطوير نموذج ماركوف لتقدير التكاليف والآثار مدى الحياة، 
بالنسبة سنوات العمر معدلة الجودة (QALYs)، لبرنامج فحص سرطان الثدي للنساء 
المعرضات لخطر كبير في سن من 40 إلى 69 عاماً. لقد استنبطنا أو انتهجنا بيانات 
-تعتمد على السن- لاحتمالية الانتقال والحدوث، بافتراض تقدم التاريخ الطبيعي بين 
مراحل السرطان، من دراسات أخرى. لقد حصلنا على تكاليف العلاج المباشر وغير المباشر 
طوال العام 2014 بالدولار الأمريكي من مسوحات لمريضات سرطان الثدي في 37 مستشفى 
صينيًا. لحساب QALY، قمنا باستنتاج تقييمات للمرافق من خلال مسوحات متعددة القطاعات 
للمرضى. قمنا بتقييم نسب متزايدة لفعالية التكاليف لمختلف السيناريوهات، وذلك 
للمقارنة مع عتبة الاستعداد للدفع.
النتائج: أسفر نموذجنا الأساسي للفحص السنوي عن نسبة متزايدة لفعالية التكلفة قدرها 
8253 دولار أمريكي/QALY، وهي أقل من عتبة الاستعداد للدفع البالغة قيمتها 23050 
دولار أمريكي/QALY. أظهرت تحليلات الحساسية أحادية الاتجاه والاحتمالية أن النتائج 
قوية. ومع استكشاف السيناريوهات المختلفة، فإن الفحص كل 3 سنوات يكون هو الأكثر 
فعالية من حيث التكلفة، مع نسبة متزايدة لفعالية التكلفة تبلغ 6671 دولارًا 
أمريكيًا/QALY. تقل فعالية تكلفة الفحص إذا لم تقم كل النساء اللواتي يتم تشخيصهن 
بالسعي للعلاج. وأخيرًا، فإن الفائدة الاقتصادية لفحص النساء اللواتي تتراوح 
أعمارهن بين 45 و69 عامًا باستخدام كل من الموجات فوق الصوتية والتصوير الشعاعي 
للثدي، مقارنةً بالفحص الشعاعي للثدي وحده، غير مؤكدة.
الاستنتاج: إن فحص سرطان الثدي في التجمعات السكانية عالية الخطورة، يعد فعالا من 
حيث التكلفة مقارنة بعدم إجراء أي فحص.

Publisher: 目的: 为 2012 年启动的中国城市基于风险的乳腺癌筛查项目建模进行成本效果分析，与不筛查的情况进行比较。.
方法: 
我们运用马尔可夫模型来估计 40-69 岁高危妇女乳腺癌筛查的终身成本和根据质量调整生命年 (QALYs) 的终身效应。我们从其他研究中推导出或采用了各年龄组发病率和转移概率数据，并假设癌症不同分期间为自然发展病程。我们从中国 37 家医院的乳腺癌患者调查中获得了 2014 年美元 (US$) 的终身直接和间接治疗费用。为了计算 QALYs，我们从横断面患者调查中得出效用分数。我们评估了不同情景下的增量成本效果比，与意愿支付最低阈值进行比较。.
结果: 我们每年筛查一次的基线模型得到的增量成本效益比为 8253 美元 /QALY，低于 23050 美元 
/QALY 的意愿支付最低阈值。单因素和概率敏感性分析表明结果可靠。在探索不同情景时，每三年进行一次筛查最具成本效果，增量成本效果比为 6671 美元 
/QALY。如果并非所有被诊断的女性都寻求治疗，筛查的成本效果会降低。最后，与单独使用乳腺钼靶 X 线摄像比较，同时采用超声和乳腺钼靶 X 线检查筛查 45-69 岁女性的经济效益尚不确定。.
结论: 与不筛查情况相比，高风险人群的乳腺癌筛查具有成本效果。.

Publisher: ЦЕЛЬ: Смоделировать экономическую эффективность программы 
скринингового обследования рака молочной железы на основе оценки риска в городах 
Китая, которая была запущена в 2012 году, при сравнении с отсутствием скрининга.
МЕТОДЫ: Авторы разработали марковскую модель для оценки затрат на медицинское 
обслуживание в течение жизни и результатов (с точки зрения количества лет жизни 
с поправкой на ее качество (QALY)) внедрения программы скринингового 
обследования рака молочной железы для женщин с высоким риском в возрасте 
40–69 лет. Авторы вывели самостоятельно или позаимствовали данные о зависимости 
частоты возникновения рака от возраста и о вероятности перехода, основываясь на 
естественной истории прогрессирования между стадиями рака по данным других 
исследований. В ходе обследований пациентов с раком молочной железы в 
37 китайских больницах были получены данные о прямых и косвенных затратах на 
медицинское обслуживание в течение жизни в долларах США (долл. США) по курсу 
2014 года. Чтобы вычислить показатель QALY, авторы получили индексы оценки 
общего состояния здоровья из перекрестного обследования пациентов. Была 
проведена оценка инкрементных коэффициентов эффективности затрат для различных 
сценариев для сравнения с порогом платежеспособности.
РЕЗУЛЬТАТЫ: Созданная авторами базовая модель ежегодного скрининга привела к 
увеличению коэффициента эффективности затрат в размере 8253 долл. США/QALY, что 
ниже порога платежеспособности в размере 23 050 долл. США/QALY. Односторонний и 
вероятностный анализ чувствительности показал, что результаты являются 
надежными. Исходя из результатов исследования различных сценариев, проведение 
скринингового обследования через каждые 3 года является наиболее рентабельным с 
инкрементным коэффициентом эффективности затрат в размере 6671 долл. США/QALY. 
Экономическая эффективность скринингового обследования снижается, если не все 
прошедшие диагностику женщины обращаются за лечением. Наконец, экономическая 
выгодность скринингового обследования женщин в возрасте 45–69 лет с 
использованием и ультразвука и маммографии по сравнению с результатами при 
использовании только маммографии является неопределенной.
ВЫВОД: Скрининговое обследование рака молочной железы среди женщин с высоким 
уровнем риска является экономически эффективным по сравнению с результатами при 
отсутствии скрининга.

DOI: 10.2471/BLT.18.207944
PMCID: PMC6083393
PMID: 30104797 [Indexed for MEDLINE]


783. J Pain Res. 2018 Jul 31;11:1391-1403. doi: 10.2147/JPR.S171395. eCollection 
2018.

Safety and efficacy of duloxetine in Japanese patients with chronic knee pain 
due to osteoarthritis: an open-label, long-term, Phase III extension study.

Uchio Y(1), Enomoto H(2), Ishida M(3), Tsuji T(4), Ochiai T(5), Konno S(6).

Author information:
(1)Department of Orthopaedic Surgery, Shimane University School of Medicine, 
Shimane, Japan, orthop@med.shimane-u.ac.jp.
(2)Bio-medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan.
(3)Clinical Research Development, Shionogi & Co. Ltd, Osaka, Japan.
(4)Medical Affairs Department, Shionogi & Co. Ltd, Osaka, Japan.
(5)Biostatistics Center, Shionogi & Co. Ltd, Osaka, Japan.
(6)Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, 
Japan.

PURPOSE: To assess long-term safety, tolerability, and efficacy of duloxetine in 
Japanese patients with chronic knee pain due to osteoarthritis.
METHODS: In this open-label extension study (NCT02335346), Japanese patients 
with knee osteoarthritis and pain (Brief Pain Inventory [BPI] - Severity average 
pain score ≥4 at start of randomized trial) who had previously received 
duloxetine 60 mg/day or placebo for 14 weeks in a double-blind randomized trial 
entered the extension and received duloxetine 60 mg/day for 48 weeks. The 
primary outcome was safety/tolerability, secondary outcomes were change in 
BPI-Severity (BPI-S) average pain, BPI-Interference (BPI-I), Patient Global 
Impression-Improvement (PGI-I), Clinical Global Impression-Improvement (CGI-I), 
36-item Short-Form Health Survey (SF36), and Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC), and exploratory outcomes were knee 
range of motion (efficacy outcome) and Kellgren-Lawrence grade (safety outcome).
RESULTS: Of 323 patients who completed the randomized trial, 93 (50 placebo, 43 
duloxetine) entered the extension. Most patients (85, 91.4%) experienced an 
adverse event, most commonly constipation, nasopharyngitis, somnolence, and dry 
mouth (≥10% of patients). There were eight serious adverse events in seven 
patients and no deaths. No obvious duloxetine-related changes were observed in 
laboratory tests, vital signs, or electrocardiograms. The change from baseline 
in BPI-S average pain score was significant throughout the extension. 
Significant reductions in BPI-I, PGI-I, CGI-I, WOMAC, and SF36 scores were also 
maintained through 52 weeks. There were no substantial changes in range of 
motion or Kellgren-Lawrence grade.
CONCLUSION: In Japanese patients with chronic knee pain due to osteoarthritis, 
long-term treatment with duloxetine was well tolerated and associated with 
sustained improvements in pain and health-related quality of life without 
radiographic deterioration.

DOI: 10.2147/JPR.S171395
PMCID: PMC6074806
PMID: 30104894


784. Case Rep Endocrinol. 2018 Jul 10;2018:8967159. doi: 10.1155/2018/8967159. 
eCollection 2018.

Bilateral Pheochromocytomas in a Patient with Y175C Von Hippel-Lindau Mutation.

Astapova O(1), Biswas A(1), DiMauro A(1), Moalem J(1), Hammes SR(1).

Author information:
(1)Division of Endocrinology and Metabolism, Department of Medicine, University 
of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.

Von Hippel-Lindau (VHL) disease, caused by germline mutations in the VHL gene, 
is characterized by metachronously occurring tumors including pheochromocytoma, 
renal cell carcinoma (RCC), and hemangioblastoma. Although VHL disease leads to 
reduced life expectancy, its diagnosis is often missed and tumor screening 
guidelines are sparse. VHL protein acts as a tumor suppressor by targeting 
hypoxia-inducible factors (HIFs) for degradation through an oxygen-dependent 
mechanism. VHL mutants with more severely reduced HIF degrading function carry a 
high risk of RCC, while mutants with preserved HIF degrading capacity do not 
cause RCC but still lead to other tumors. VHL disease is classified into 
clinical types (1 and 2A-2C) based on this genotype-phenotype relationship. We 
report a case of bilateral pheochromocytomas and no other VHL-related tumors in 
a patient with Y175C VHL and show that this mutant preserves the ability to 
degrade HIF in normal oxygen conditions but, similar to the wild-type VHL 
protein, loses its ability to degrade HIF under hypoxic conditions. This study 
adds to the current understanding of the structure-function relationship of VHL 
mutations, which is important for risk stratification of future tumor 
development in the patients.

DOI: 10.1155/2018/8967159
PMCID: PMC6076969
PMID: 30105105


785. APL Bioeng. 2018 Sep;2(3):036101. doi: 10.1063/1.5019592. Epub 2018 Jul 17.

Preserved cardiac function by vinculin enhances glucose oxidation and extends 
health- and life-span.

Sessions AO(1), Min P(2), Cordes T(2), Weickert BJ(2), Divakaruni AS(3), Murphy 
AN(3), Metallo CM(2), Engler AJ(1)(2)(4).

Author information:
(1)Biomedical Sciences Program, UC San Diego, La Jolla, California 92093, USA.
(2)Department of Bioengineering, UC San Diego, La Jolla, California 92093, USA.
(3)Department of Pharmacology, UC San Diego, La Jolla, California 92093, USA.
(4)Sanford Consortium for Regenerative Medicine, La Jolla, California 92037, 
USA.

Despite limited regenerative capacity as we age, cardiomyocytes maintain their 
function in part through compensatory mechanisms, e.g., Vinculin reinforcement 
of intercalated discs in aged organisms. This mechanism, which is conserved from 
flies to non-human primates, creates a more crystalline sarcomere lattice that 
extends lifespan, but systemic connections between the cardiac sarcomere 
structure and lifespan extension are not apparent. Using the rapidly aging fly 
system, we found that cardiac-specific Vinculin-overexpression [Vinculin 
heart-enhanced (VincHE)] increases heart contractility, maximal cardiac 
mitochondrial respiration, and organismal fitness with age. Systemic metabolism 
also dramatically changed with age and VincHE; steady state sugar 
concentrations, as well as aerobic glucose metabolism, increase in VincHE and 
suggest enhanced energy substrate utilization with increased cardiac 
performance. When cardiac stress was induced with the complex I inhibitor 
rotenone, VincHE hearts sustain contractions unlike controls. This work 
establishes a new link between the cardiac cytoskeleton and systemic glucose 
utilization and protects mitochondrial function from external stress.

DOI: 10.1063/1.5019592
PMCID: PMC6086353
PMID: 30105314


786. CNS Drugs. 2018 Aug;32(8):785-796. doi: 10.1007/s40263-018-0562-0.

Cladribine Tablets: A Review in Relapsing MS.

Deeks ED(1).

Author information:
(1)Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
demail@springer.com.

Erratum in
    CNS Drugs. 2019 Feb;33(2):193.

Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes 
lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. 
Cladribine tablets (Mavenclad®) represent the first short-course oral 
disease-modifying drug (DMD) for use in MS. The tablets, administered in two 
short courses 1 year apart, are indicated for the treatment of adults with 
highly active relapsing MS on the basis of data from pivotal clinical trials, 
including the phase 3 study CLARITY and its extension. A cumulative cladribine 
tablets dose of 3.5 mg/kg administered in this fashion in CLARITY reduced 
clinical relapse, disability progression and MRI-assessed disease activity and 
also improved some aspects of health-related quality of life (HR-QOL) versus 
placebo over 96 weeks in adults with relapsing-remitting MS (RRMS). Moreover, in 
the 96-week extension (plus 24 weeks' supplemental follow-up), no additional 
clinical benefit was gained from continuing versus discontinuing cladribine 
tablets after the first two annual courses of therapy, although MRI activity was 
more notable in a subset of cladribine tablet recipients who discontinued the 
drug. In post hoc analyses of CLARITY and/or a phase 2b trial, benefits of 
cladribine tablets were seen in patients with high disease activity (HDA) 
relapsing MS that were sometimes greater than in patients without HDA. 
Cladribine tablets have an acceptable tolerability profile and do not appear to 
be associated with an increased risk of overall infection or with an increased 
risk of malignancy (vs. matched reference populations). Active comparisons and 
longer-term follow-up would be beneficial, although current data indicate that 
for adults with highly active relapsing MS, cladribine tablets are an effective 
treatment option with the convenience of low-burden, short-course, oral 
administration.

DOI: 10.1007/s40263-018-0562-0
PMCID: PMC6353806
PMID: 30105527 [Indexed for MEDLINE]

Conflict of interest statement: Emma Deeks is a salaried employee of 
Adis/Springer, is responsible for the article content and declares no relevant 
conflicts of interest.


787. Lakartidningen. 2018 Aug 14;115:E7Y3.

Medellivslängden ökar inte lika mycket längre - Sverige har kommit på 
efterkälken – och kanske närmar vi oss gränsen för hur gamla vi kan bli.

[Article in Swedish]

Modig K(1), Drefahl S(2), Ahlbom A(3).

Author information:
(1)Karolinska Institutet - Institute of Environmental Medicine Stockholm, Sweden 
Karolinska Institutet - Institute of Environmental Medicine Stockholm, Sweden.
(2)Stockholm University - Sociology Stockholm, Sweden Stockholm University - 
Sociology Stockholm, Sweden.
(3)Karolinska Institutet - institute of Environmental Medicine Stockholm, Sweden 
-.

PMID: 30106457 [Indexed for MEDLINE]


788. Nephrol Dial Transplant. 2020 Mar 1;35(3):503-511. doi: 10.1093/ndt/gfy254.

Vascular access placement and mortality in elderly incident hemodialysis 
patients.

Ko GJ(1)(2), Rhee CM(1), Obi Y(1), Chang TI(1)(3), Soohoo M(1), Kim TW(1)(4), 
Kovesdy CP(5)(6), Streja E(1), Kalantar-Zadeh K(1)(7).

Author information:
(1)Harold Simmons Center for Kidney Disease Research and Epidemiology, 
University of California Irvine, School of Medicine, Orange, CA, USA.
(2)Department of Internal Medicine, Korea University School of Medicine, Seoul, 
Korea.
(3)Department of Internal Medicine, National Health Insurance Service Medical 
Center, Ilsan Hospital, Goyangshi, Gyeonggi-do, Korea.
(4)Department of Internal Medicine, Soon Chun Hyang University Hospital, Gumi, 
Korea.
(5)Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, TN, 
USA.
(6)Division of Nephrology, Department of Medicine, University of Tennessee 
Health Science Center, Memphis, TN, USA.
(7)Department of Medicine, Tibor Rubin Veteran Affairs Medical Center, Long 
Beach, CA, USA.

BACKGROUND: Arteriovenous fistulas (AVFs) are the preferred vascular access type 
in most hemodialysis patients. However, the optimal vascular access type in 
octogenarians and older (≥80 years) hemodialysis patients remains widely debated 
given their limited life expectancy and lower AVF maturation rates.
METHODS: Among incident hemodialysis patients receiving care in a large national 
dialysis organization during 2007-2011, we examined patterns of vascular access 
type conversion in 1 year following dialysis initiation in patients <80 versus 
≥80 years of age. Among a subcohort of patients ≥80 years of age, we examined 
the association between vascular access type conversion and mortality using 
multivariable survival models.
RESULTS: In the overall cohort of 100 804 patients, the prevalence of 
AVF/arteriovenous graft (AVG) as the primary vascular access type increased 
during the first year of hemodialysis, but plateaued thereafter. Among 8356 
patients ≥80 years of age and treated for >1 year, those with initial AVF/AVG 
use and placement of AVF from a central venous catheter (CVC) had lower 
mortality compared with patients with persistent CVC use. When the reference 
group was changed to patients who had AVF placement from a CVC in the first year 
of dialysis, those with initial AVF use had similar mortality. A longer duration 
of CVC use was associated with incrementally worse survival.
CONCLUSIONS: Among incident hemodialysis patients ≥80 years of age, placement of 
an AVF from a CVC within the first year of dialysis had similar mortality 
compared with initial AVF use. Our data suggest that initial CVC use with later 
placement of an AVF may be an acceptable option among elderly hemodialysis 
patients.

© The Author(s) 2018. Published by Oxford University Press on behalf of 
ERA-EDTA. All rights reserved.

DOI: 10.1093/ndt/gfy254
PMCID: PMC7057539
PMID: 30107612 [Indexed for MEDLINE]


789. Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Aug 6;52(8):837-841. doi: 
10.3760/cma.j.issn.0253-9624.2018.08.012.

[Evaluation of economic outcomes of "hepatitis B vaccine event reported by 
media" in China, 2013].

[Article in Chinese; Abstract available in Chinese from the publisher]

Zhang SX(1), Sun PP, Xia Y.

Author information:
(1)Institute of Communicabal Disease Control and Prevention, Shenzhen Center for 
Disease Control and Prevention, Shenzhen 518055, China.

Objective: To edentify the increased cost, the decreased benefits and 
effectiveness of hepatitis B vaccine event reported by media in 2013 in China 
both in Chinese nationwide and in Shenzhen. Methods: The decision 
analytic-Markov models were constructed. The cohort born in 2013 in nationwide 
and in Shenzhen were respectively introduced to the models. The vaccination 
coverage and the rates of antibody to hepatitis B surface antigen were 
determined as major parameters. The average costs and benefits per case, the 
effectiveness which included the numbers of hepatitis B virus (HBV) infection 
and the patients with HBV-related diseases, the average quality-adjusted life 
years (QALYs) per case were calculated from the medical-care and societal 
perspectives. The benefit cost ratio (BCR), ratio of the total costs and the net 
QALYs were as indicators of cost-benefit and cost-effectiveness analysis, 
respictively. Results: In nationwide, the BCRs decreased from 9.10 and 8.58 to 
2.48 and 2.43, respectively, because the average costs increased to 6 796.60 
yuan (RMB) and 8 451.45 yuan, and average benefits decreased to 6 799.57 yuan 
and 8 484.41 yuan, respectively, from the medical-care and societal 
perspectives. In Shenzhen, the BCRs decreased from 16.21 and 14.51 to 3.11 and 
3.04 with the average costs of 5 244.88 yuan and 8 937.64 yuan, and average 
benefits of 5 248.11 yuan and 8 977.27 yuan. Totally, the increase of 2.1314 
million and 181 hundreds of the HBV infectors occurred for the event in 
nationwide and in Shenzhen, respectively. Of all the infectors increased the 
most, the numbers of acute and chronic hepatitis B were 1 904 hundreds and 807 
hundreds in nationwide, 794 and 395 in Shenzhen, espectively. The decreases of 
average QALY per case were 0.119 8 in nationwide and 0.090 6 in Shenzhen. The 
costs per averted a QALY increased from 6 231.90 yuan to 22 883.51 yuan in 
nationwide, from 3 567.25 yuan to 1 8571.49 yuan in Shenzhen (for medical-care 
perspective), from 8 252.79 yuan and 6 807.45 yuan to 29 091.92 yuan and 32 
553.60 yuan (for societal perspective). Conclusion: The hepatitis B vaccine 
event reported by media in 2013 in China caused the costs increased, both 
benefits and the economic values obviously decreased.

Publisher: 目的： 探讨因发生"乙型肝炎疫苗（HepB）事件"导致全国及深圳市增加的投入、损失的经济效益和效果。 方法： 
采用决策分析Markov模型，分别以2013年我国出生人口数为研究队列，以HepB接种率和乙型肝炎表面抗体（抗-HBs）阳转率为相关参数；从医疗卫生和社会角度分别计算和比较事件发生与否导致的人均成本、效益和效果，其中效果指标包括乙型肝炎病毒（HBV）感染和乙型肝炎相关疾病数、人均质量调整生命年（QALY）；成本效益和成本效果分析指标包括效益成本比（BCR）和总成本与净效果之比（元/QALY）。 
结果： 从医疗卫生和社会角度看，与未发生"乙型肝炎疫苗事件"相比，发生该事件使全国HepB接种者的人均成本分别增加了6 796.60和8 
451.45元，而人均效益分别减少了6 799.57和8 
484.41元；BCR分别由9.10和8.58减低为2.48和2.43。而深圳市HepB接种对象人均成本分别增加了5 244.88和8 
937.64元，而人均效益分别减少了5 248.11和8 
977.27元；BCR分别由16.21和14.54减低为3.11和3.04。发生"乙型肝炎疫苗事件"，使全国和深圳市HBV感染例数分别增加了213.14万和1.81万例，以急性乙型肝炎和慢性乙型肝炎增加例数最多，全国分别增加了19.03万和8.07万例，深圳市分别增加了794和395例；而全国和深圳市总成本与净效果之比分别减少了0.12和0.09元/QALY；从医疗卫生角度，每获得1个QALY需要的成本，由6 
231.90和3 567.25元分别升高到了22 883.51和18 571.49元；从社会角度，由8 252.79和6 807.45元分别升高到29 
091.92和32 553.60元。 结论： "乙型肝炎疫苗事件"造成了乙型肝炎免疫预防成本的增加和效益的减少，经济学价值降低。.

DOI: 10.3760/cma.j.issn.0253-9624.2018.08.012
PMID: 30107719 [Indexed for MEDLINE]


790. Trials. 2018 Aug 14;19(1):438. doi: 10.1186/s13063-018-2814-1.

The Heidelberg Milestones Communication Approach (MCA) for patients with 
prognosis <12 months: protocol for a mixed-methods study including a randomized 
controlled trial.

Siegle A(1)(2), Villalobos M(3), Bossert J(4), Krug K(4), Hagelskamp L(3)(5), 
Krisam J(6), Handtke V(3), Deis N(7), Jünger J(7), Wensing M(4), Thomas M(3).

Author information:
(1)Department of Thoracic Oncology, Thoraxklinik Heidelberg, Heidelberg 
University Hospital, Translational Lung Research Center Heidelberg (TLRC-H), 
German Center for Lung Research (DZL), Röntgenstraße 1, D-69126, Heidelberg, 
Germany. anja.siegle@med.uni-heidelberg.de.
(2)German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, 
Germany. anja.siegle@med.uni-heidelberg.de.
(3)Department of Thoracic Oncology, Thoraxklinik Heidelberg, Heidelberg 
University Hospital, Translational Lung Research Center Heidelberg (TLRC-H), 
German Center for Lung Research (DZL), Röntgenstraße 1, D-69126, Heidelberg, 
Germany.
(4)Department of General Practice and Health Services Research, Heidelberg 
University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
(5)German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, 
Germany.
(6)Institute of Medical Biometry and Informatics, Heidelberg University 
Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
(7)The German National Institute for State Examinations in Medicine, Pharmacy 
and Psychotherapy, Große Langgasse 8, 55116, Mainz, Germany.

BACKGROUND: The care needs of patients with a limited prognosis (<12 months 
median) are complex and dynamic. Patients and caregivers must cope with many 
challenges, including physical symptoms and disabilities, uncertainty. and 
compromised self-efficacy. Healthcare is often characterized by disruptions in 
the transition between healthcare providers. The Milestones Communication 
Approach (MCA) is a structured, proactive, interprofessional concept that 
involves physicians and nurses and is aimed at providing coherent care across 
the disease trajectory. This study aims to evaluate these aspects of MCA: (1) 
